BioSpace News Archive

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced positive topline results from its OCS donors after circulatory death Heart Trial.

Protagonist Therapeutics, Inc. announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera have been selected for oral presentations at the American Society of Hematology 2021 Annual Meeting taking place December 11-14, 2021.

Berkshire Biomedical Corporation announced today that John Timberlake, Chief Executive Officer of Berkshire Biomedical, will showcase the Company and its Computerized Oral Prescription Administration (COPA®) System as they participate in the LSX 6th Annual Investment Showcase Hybrid taking place from November 8-15, 2021, both in person from the Hilton Waldorf in London and virtually.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update.

Concert Pharmaceuticals, Inc. announced that it has entered into an agreement with BVF Partners L.P. and RA Capital Management to raise gross proceeds of $65 million.

Personalis, Inc., a leader in advanced genomics for cancer and population sequencing, reported financial results for the third quarter ended September 30, 2021.

PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, announced that it has raised $75.5 million in Series B financing.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on November 3, 2021 as inducements material to each employee entering into employment with KalVista.

VectivBio Holding AG today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021 at 9:40 a.m. ET.